Covering: Biology - Neuroscience - MedicineCovering: Biology - Neuroscience - Medicine
All explained papers

Nature Medicine, 2026 Jul 23 · 6 min read

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

There is a skin disease that causes recurring painful abscesses, lumps, and tunnels under the skin, mainly in the armpits, groin, and under the breasts. It can be severely disabling, deeply affects quality of life, and has historically had very few effective treatments. In Nature Medicine, two phase 3 randomized controlled trials of an oral drug called povorcitinib report significant benefit in people with this condition.

The disease is hidradenitis suppurativa, or HS, a long-lasting inflammatory skin condition. The name roughly means "pus-forming inflammation of sweat glands." It strikes skin folds and areas rich in hair follicles and a type of sweat gland called apocrine glands: armpits, groin, buttocks, inner thighs, and under the breasts. It starts with painful deep lumps, moves on to abscesses that burst and drain, and in advanced stages forms tunnels under the skin, called sinus tracts, that connect the sores.

Living with it is hard. Pain is often severe and constant. The drainage smells, which brings heavy social and psychological weight. People avoid exercise, social situations, and some kinds of clothing. Depression and anxiety are far more common than in the general population. HS often begins in the teenage years or young adulthood and can progress over decades, and it affects work, since many patients cannot hold jobs that require certain clothing or sustained physical effort.

The exact cause is not fully understood, but the central event is a blocked hair follicle in a skin fold. Material builds up behind the blockage like a clogged drain, the follicle bursts, and its contents set off a dramatic inflammatory reaction in the surrounding skin. Bacteria join in later, but HS is not mainly an infection. That is why antibiotics alone, long the usual treatment, deal with the bacteria but not the inflammation driving the disease. Genes play a part: about a third of patients have a family history.

Doctors stage HS with the Hurley system. Stage one means one or more abscesses without tunnels or scarring. Stage two means recurring abscesses with tunnels and scarring, but in separate patches with normal skin between them. Stage three means widespread disease, or many connected tunnels and abscesses across a whole body region. Moving from stage one to three usually takes years and can be sped up by obesity, smoking, and hormonal changes. Most drug trials enroll moderate-to-severe disease, roughly stages two and three.

For most of the disease's history, treatment meant antibiotics for flares, draining abscesses, and surgically cutting out affected skin, which only suits localized disease. The first targeted drug, adalimumab, was approved in 2015. It is an antibody that blocks tumor necrosis factor, a key inflammatory signal. It helps a meaningful share of patients but not all, and many respond poorly. Secukinumab, which blocks a signal called IL-17A, was approved for HS in 2023 and added another option. But more choices were still needed, especially pills.

A pill matters for several reasons. The injected antibody drugs are expensive, require clinic visits or training to self-inject, and carry immune-suppression risks some patients prefer to avoid or cannot access. An effective pill can be prescribed by a family doctor, picked up at a pharmacy, and taken at home. For a disease of younger people, many of whom cannot easily see a skin specialist, that widens access considerably.

Povorcitinib is a JAK1 inhibitor. JAK stands for Janus kinase, a family of enzymes inside immune cells that relay messages from the cell surface to the nucleus, where they switch on inflammation genes. When cytokines, the signaling proteins that drive inflammation, land on receptors outside the cell, they activate JAK enzymes, which pass the message along to proteins that travel to the nucleus and turn on more inflammation.

Blocking JAK1 mutes many cytokine signals at once, including interleukin-4, interleukin-13, interleukin-17, and others, all linked to HS. Think of a telephone exchange: instead of blocking one caller, you switch off a hub that many callers route through.

JAK inhibitors are a well-established class. Tofacitinib was the first, approved for rheumatoid arthritis, and the class has since spread to psoriatic arthritis, ulcerative colitis, atopic dermatitis, and alopecia areata. Each drug blocks a different mix of JAK family members, which affects both how well it works in a given disease and its safety. Povorcitinib is selective for JAK1, which is thought to limit effects on the other members.

Here is what the published abstract reports; the full text is behind a paywall. The two trials, STOP-HS1 and STOP-HS2, are the matched pair typical of phase 3 testing in a new disease. Two independent trials give sturdier evidence than one, and regulators usually require it. Both compared povorcitinib with placebo in people with moderate-to-severe HS.

The main measure in HS trials is usually HiSCR, the Hidradenitis Suppurativa Clinical Response: at least a fifty percent drop in active sores, with no increase in abscesses or draining tunnels. Both trials showed a statistically significant benefit for povorcitinib on this measure.

Two phase 3 trials that agree are the gold standard for showing a drug works. Both hitting the same main goal means the result is not a one-off. HiSCR50 is a validated measure used across HS trials, so the result can be compared with the evidence for other HS drugs and understood by doctors and insurers.

What the abstract does not show matters too. It does not allow a judgment of how large the benefit was, what the safety events were in detail, or how long the response lasts after the trial. All of those shape how the drug will be used.

JAK inhibitors as a class carry warnings in several countries about a higher risk of serious infections, because blocking these signals weakens part of the body's immune watch. In the United States the class also carries a boxed warning about heart and blood vessel events, cancer, and blood clots, added after a large trial of tofacitinib in rheumatoid arthritis showed higher rates than with a tumor necrosis factor blocker.

How much those class risks apply to povorcitinib, which is more selective, and to people with HS, who skew younger and may have a different baseline heart risk than people with rheumatoid arthritis, will be part of the regulatory review. That makes the safety data in the full paper an important piece.

Patients with HS have long described feeling dismissed by doctors. The disease is visually dramatic but sits in areas people do not show in a clinic, which feeds underdiagnosis. The smelly drainage leads to assumptions about hygiene rather than recognition of an inflammatory disease. Its links to obesity and smoking, which are related conditions and possible aggravating factors but not causes, add to the stigma. Many patients describe years of misdiagnosis, often as folliculitis, and repeated antibiotic courses that never touched the underlying biology. Povorcitinib and the growing HS pipeline are part of a late recognition that this is a serious, distinct inflammatory disease that deserves systematic study.

Atopic dermatitis, or chronic eczema, offers a useful comparison. For decades it was managed with steroid creams and broad immune suppressants like cyclosporine, with few options for severe disease. Dupilumab, approved in 2017, transformed care as a targeted antibody with strong results and safety. JAK inhibitors followed and added pills many patients prefer. HS is now in a similar spot: adalimumab brought the first effective targeted drug, and the current wave of trials, including STOP-HS, is adding pills and new mechanisms. HS seems to be following the eczema path, roughly eight to ten years behind.

Two phase 3 trials in one paper reflect industry's judgment that the market justifies the investment, which also means patients get a strong evidence base. HS affects roughly one percent of people, which means millions of patients worldwide with poorly controlled disease. The market is real and so is the unmet need. STOP-HS shows the disease is now taken seriously enough to produce the kind of evidence that leads to approval and, eventually, to covered prescriptions for patients who have had few options.

HS mostly affects younger adults, often in their twenties and thirties, during the years when careers and relationships are built. That changes the stakes compared with diseases of older age, and it changes the economics. The burden of an undertreated chronic disease in a young person builds over a longer working life: lost productivity, mental health costs, repeated emergency visits for draining abscesses, adding up over decades in ways a short-term cost analysis misses. Health assessments that use quality-adjusted life years, a measure that counts both length and quality of life, tend to look more favorably on treatments for high-burden conditions in younger people than simple cost comparisons would suggest.

The paper is PMID 42493571, published in Nature Medicine on July 23, 2026. This account is based on the published abstract; the full text is behind a paywall.